Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more) Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mustang Bio Inc MBIO

Healthcare Biotechnology
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene... see more

Recent & Breaking News (NDAQ:MBIO)

Mustang Bio to Present at Scientific Conferences in September 2019

GlobeNewswire September 9, 2019

Mustang Bio Adopts CryoStor® Freeze Media and evo® Cold Chain System for Cell and Gene Therapy Manufacturing and Distribution

PR Newswire September 3, 2019

Mustang Bio to Present at September 2019 Investor Conferences

GlobeNewswire August 29, 2019

Mustang Bio Announces License Agreement with CSL Behring for the Cytegrity(TM) Stable Producer Cell Line for the Production of MB-107 Lentiviral Gene Therapy

GlobeNewswire August 27, 2019

Mustang Bio and St. Jude Children's Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA

GlobeNewswire August 22, 2019

Mustang Bio Announces $9.28 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-103 in HER2-Positive Breast Cancer with Brain Metastases

GlobeNewswire August 13, 2019

Mustang Bio to Present at 11th Annual Bioprocessing Summit

GlobeNewswire August 12, 2019

Mustang Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire August 9, 2019

FDA Clears IND for Mustang Bio's MB-102 (CD123 CAR T)

GlobeNewswire August 5, 2019

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Acute Myeloid Leukemia

GlobeNewswire July 24, 2019

Mustang Bio and St. Jude Children's Research Hospital to Participate in Panel Discussion at Boston CEO 2019

GlobeNewswire May 23, 2019

Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019

GlobeNewswire May 13, 2019

Mustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights

GlobeNewswire May 10, 2019

Mustang Bio Announces Full Exercise of Option

GlobeNewswire May 8, 2019

Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein

GlobeNewswire May 8, 2019

Mustang Bio Announces Pricing of Public Offering of Common Stock

GlobeNewswire April 30, 2019

Mustang Bio Announces Proposed Public Offering of Common Stock

GlobeNewswire April 29, 2019

FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet

Press Releases April 29, 2019

St. Jude Children's Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine

GlobeNewswire April 17, 2019

Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

GlobeNewswire December 20, 2018